Nucala 100 mg, Lyophilisat zur Herstellung einer Injektionslösung
7680657310016
CH-65731
R03DX09
03.04.5.
1 / 3
google
Details
- Product number
- 6573101
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- Praeparatio cryodesiccata: mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus corresp. natrium 1.5-2 mg, polysorbatum 80, acidum hydrochloricum q.s. ad pH pro vitro.
Articles (1)
Nucala 100 mg, Lyophilisat zur Herstellung einer Injektionslösung
Lyophilisat
1
Official Swissmedic V2 data
Additional information from the official database
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
PRC
|
100.0 MG | Substance | Wirkstoff (Principe actif) |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HBESI |
|
PRC
|
- | Substance | HNIDK |
Authorization holder
GlaxoSmithKline AG
6340 Baar
Authorization information
- Swissmedic authorization number
- 65731
- Drug name
- Nucala, Lyophilisat zur Herstellung einer Injektionslösung
- Galenic form
- PULVL
- ATC Code
- R03DX09
- Authorization status
- Revoked/Withdrawn
- Dispensation category
- B
- First authorization
- 07/04/2016
- Authorization expiration date
- 30/06/2025
- IT number
- 03.04.5.
- Domain
- Human medicine
Packaging details
- Description (FR)
- NUCALA subst sèche 100 mg/ml flac
- Description (DE)
- NUCALA Trockensub 100 mg/ml Durchstf
- Market launch
- 07/04/2016
- Market withdrawal
- 24/06/2025
- Narcotic (BTM)
- No